Tides Express | Novogene’s HPV therapeutic DNA nucleic acid drug achieves breakthrough progress in Phase I clinical trials

On August 20, 2024, the content team of Sinopharm Biopharmaceuticals announced that NWRD08, an HPV therapeutic nucleic acid drug independently developed by Novobio, has made breakthrough progress in its registered clinical phase I project at Peking Union Medical College Hospital. The first subject – a patient with HPV16 positive infection and recurrent HSIL (high-grade squamous intraepithelial neoplasia of the cervix), underwent one course of treatment with NWRD08 and achieved HPV16 negative conversion and pathological benign transformation of HSIL tissue within 12 weeks, with lesion clearance!